Cadent Therapeutics to Present at the 5th Annual BMO Private Company Showcase
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 14, 2019--
Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the 5 th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:00 am ET in New York City.
About Cadent Therapeutics
Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive impairment. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 clinical studies for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Institutes for Biomedical Research and Slater Technology Fund. For more information, please visit cadenttx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191014005178/en/
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Cadent Therapeutics
Copyright Business Wire 2019.
PUB: 10/14/2019 07:00 AM/DISC: 10/14/2019 07:00 AM